Slowing Disability in MS

Episode Summary

Executive Summary: The discussion centers on Immunic’s vitofudimus calcium, a once-daily oral MS therapy designed to combine anti-inflammatory effects with direct neuroprotection via NUR1 activation. CEO Daniel Vitt argues current MS drugs mostly suppress relapses but fail to slow neurodegeneration and disability progression, especially in progressive MS. He outlines encouraging phase 2 data, ongoing phase 3 work, a planned 2027 NDA filing, and a large financing to support commercialization.

Main Topics: Unmet need in multiple sclerosis (Priority: 5/5): MS is framed as a disease where current therapies control inflammation and relapses but largely miss the slower neurodegeneration that drives long-term disability, particularly in progressive forms. Dual mechanism of vitofudimus calcium (Priority: 5/5): The candidate is described as both a DHO-DH inhibitor to reduce inflammation and a NUR1 activator intended to protect neurons from cell death, making it potentially disease-modifying beyond relapse control. Clinical evidence from phase 2 studies (Priority: 4/5): Vitt highlights strong MRI-based anti-inflammatory effects in relapsing MS, biomarker improvements, and early signs of reduced disability progression, plus supportive data in progressive MS. Progressive MS opportunity (Priority: 5/5): The company argues progressive MS is especially underserved, with little approved therapy and a need for drugs that can address progression even without active inflammation. Safety and tolerability as a differentiator (Priority: 4/5): A benign safety profile, low monitoring burden, and absence of common oral-therapy drawbacks such as GI issues, hair loss, and lab abnormalities are presented as major adoption advantages. Commercial strategy and financing (Priority: 4/5): Immunic’s oversubscribed private placement is intended to fund phase 3 completion, NDA submission, launch preparation, and a progressive MS program as the company transitions toward commercialization. Investor and market positioning (Priority: 3/5): Vitt positions vitofudimus as a potential first-line oral option and a switch option for patients leaving higher-risk therapies, including anti-CD20 agents, due to infections or tolerability concerns.

Key Arguments: Current MS therapies are effective at suppressing inflammatory relapses but do not adequately address smoldering neurodegeneration, the main driver of long-term disability progression. Vitofudimus calcium is differentiated by its dual action: DHO-DH inhibition for anti-inflammatory activity and NUR1 activation for neuronal protection. NUR1 activation is presented as a first-in-class mechanism with the potential to directly protect neurons from cell death, which could matter most in progressive MS. Phase 2 data in relapsing MS showed strong reductions in MRI lesion activity and biomarker signals, supporting proof of concept for both anti-inflammatory and neuroprotective effects. Progressive MS represents a major unmet need because patients may worsen even without active relapse-driven inflammation, making a neuroprotective mechanism especially valuable. The drug’s favorable safety and tolerability profile could reduce monitoring burden and make it easier to use than many current oral or biologic therapies. Immunic believes the drug can fit both as an early oral option and as a switch option for patients discontinuing therapies with infection risks, particularly anti-CD20 treatments. A large financing was structured to fully fund key development milestones and de-risk the path to an NDA, launch, and a PPMS trial.

Data Points: MS prevalence: almost 3 million people worldwide - Vitt described the overall global burden of multiple sclerosis. Age at diagnosis: typically in the 20s and 30s - MS is said to begin early in adult life. Sex ratio in relapsing MS: 4:1 women to men - Vitt noted MS is more common in women, especially in relapsing disease. Sex ratio in progressive MS: 1:1 women to men - Vitt contrasted the demographic pattern in progressive disease. Phase 2 relapsing MS study size: 268 patients - The EMPhASIS study tested three doses in relapsing MS. Dose levels with strongest effect: 30 mg and 45 mg - These doses produced similar strong anti-inflammatory results in the phase 2 relapsing study. Reduction in active lesions: 76% to 78% - MRI-measured cumulative active and gadolinium-enhancing lesions were reduced in relapsing MS. Biomarker: serum neurofilament light chain - Used as a marker of neuroaxonal injury/protection in phase 2 studies. Future NDA filing timing: mid-2027 - Expected filing timing if phase 3 data are positive. Potential launch timing: mid-2028 - Projected launch in relapsing MS if regulatory review is successful. PPMS phase 3 readout: 2030 - Expected readout for the planned primary progressive MS study. Private placement size: up to $400 million - Financing intended to support development, launch, and PPMS work. Upfront financing: $200 million - Immediate proceeds from the private placement. Warrant-linked financing: another $200 million - Additional capital contingent on phase 3 results and warrant execution. EBV/MS risk association: about 32-fold increased MS risk - Vitt cited a cohort study linking Epstein-Barr virus infection to later MS risk.

Pivotal Quotes: "the underlying disability progression is driven by two things. And on top of the relapse activity, this is driven by also a smoldering destruction of neurons" — Daniel Vitt: Explaining the key unmet need in MS and why current therapies are insufficient "it is a new mode of action. It's a new target for MS. And this, I think, really has the potential to change the way we treat MS in the future." — Daniel Vitt: Describing NUR1 activation as the differentiating feature of vitofudimus calcium "for the patient, I think still the confirmed disability progression is, that's the elephant in the room" — Daniel Vitt: Emphasizing why progression-slowing efficacy matters most clinically

Implications: If phase 3 data confirm the phase 2 signal, Immunic could become a rare oral MS therapy that addresses both relapse control and disability progression, especially in progressive disease. The large financing and planned PPMS trial suggest a credible path to commercialization and broader competitive pressure on existing MS standards.